Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ZNTL 
Zentalis Pharmaceuticals Llc (ZNTL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: ZNTL (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $6.19
1 Year Target Price $6.19
| 3 | Strong Buy |
| 1 | Buy |
| 6 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -65.16% | Avg. Invested days 23 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 106.76M USD | Price to earnings Ratio - | 1Y Target Price 6.19 |
Price to earnings Ratio - | 1Y Target Price 6.19 | ||
Volume (30-day avg) 10 | Beta 1.72 | 52 Weeks Range 1.01 - 5.44 | Updated Date 08/15/2025 |
52 Weeks Range 1.01 - 5.44 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.28 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.535 | Actual -0.37 |
Profitability
Profit Margin - | Operating Margin (TTM) -638.12% |
Management Effectiveness
Return on Assets (TTM) -25.41% | Return on Equity (TTM) -49.55% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -158980530 | Price to Sales(TTM) 3.97 |
Enterprise Value -158980530 | Price to Sales(TTM) 3.97 | ||
Enterprise Value to Revenue 7.77 | Enterprise Value to EBITDA -2.31 | Shares Outstanding 72135504 | Shares Floating 49978327 |
Shares Outstanding 72135504 | Shares Floating 49978327 | ||
Percent Insiders 13.54 | Percent Institutions 72.32 |
Upturn AI SWOT
Zentalis Pharmaceuticals Llc
Company Overview
History and Background
Zentalis Pharmaceuticals, LLC is a biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancer. Founded in 2014, the company went public in April 2020. Zentalis is dedicated to translating its science into medicines for patients with cancer.
Core Business Areas
- Oncology Drug Discovery and Development: Focuses on developing small molecule therapeutics to treat various cancers by targeting key oncogenic drivers and resistance mechanisms. Zentalis has a diverse pipeline of product candidates in clinical and preclinical development, focusing on cancer pathways and resistance.
Leadership and Structure
Dr. Kimberly Blackwell is the CEO. The company operates with a leadership team focused on R&D, clinical development, and commercial strategy. Zentalis also has a scientific advisory board made up of experts in the field of oncology
Top Products and Market Share
Key Offerings
- ZN-c3: A selective oral Wee1 inhibitor that is designed to block the Wee1 kinase from inhibiting cell division. ZN-c3 is being evaluated in clinical trials for various solid tumors. Competitors in the Wee1 inhibitor space include companies like Ataxia and Syntekabio. Market share data is not readily available, as the drug is still in clinical development.
- ZN-d6: A selective oral ERD degrader designed to inhibit ER in breast cancer cells. ZN-d6 is being evaluated in clinical trials. Competitors in the ERD degrader space include companies like Radius Health and Menarini Group. Market share data is not readily available, as the drug is still in clinical development.
Market Dynamics
Industry Overview
The oncology therapeutics market is characterized by high growth, driven by an aging population and increasing cancer incidence. The market is also marked by intense competition, rapid innovation, and stringent regulatory requirements.
Positioning
Zentalis is a clinical-stage biopharmaceutical company focusing on oncology, differentiating itself through its focus on small molecule therapeutics targeting fundamental cancer pathways. Its competitive advantage lies in its innovative drug discovery platform and experienced management team.
Total Addressable Market (TAM)
The global oncology market is estimated to be worth hundreds of billions of dollars. Zentalis is focused on specific subsets of cancers, positioning them to capture a portion of the TAM related to their lead product candidates.
Upturn SWOT Analysis
Strengths
- Innovative drug discovery platform
- Experienced management team
- Promising clinical pipeline
- Strong intellectual property portfolio
- Targeting of key oncogenic drivers and resistance mechanisms
Weaknesses
- Reliance on clinical trial success
- High R&D costs
- Limited commercialization experience
- Dependence on key personnel
- Limited product portfolio relative to larger companies
Opportunities
- Expanding pipeline through internal discovery and strategic collaborations
- Securing partnerships for late-stage development and commercialization
- Acquiring complementary technologies or assets
- Addressing unmet medical needs in specific cancer subtypes
- Potential for accelerated approval pathways
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from larger pharmaceutical companies
- Patent challenges
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- AZN
- MRK
- BMY
Competitive Landscape
Zentalis competes with both large pharmaceutical companies and smaller biotechnology firms in the oncology space. Its competitive advantage lies in its targeted approach and innovative drug discovery platform.
Growth Trajectory and Initiatives
Historical Growth: Zentalis has grown from a private startup to a publicly traded company with a clinical-stage pipeline.
Future Projections: Future growth will depend on the success of clinical trials and subsequent commercialization of its product candidates. Analyst projections vary based on clinical milestones.
Recent Initiatives: Recent initiatives include advancing the clinical development of ZN-c3 and ZN-d6, presenting data at scientific conferences, and securing financing to support R&D efforts.
Summary
Zentalis Pharmaceuticals is a clinical-stage company focused on cancer therapeutics and has a promising pipeline. However, like all clinical-stage biotechs, Zentalis faces risks associated with clinical trials. Strong intellectual property and strategic partnerships will be essential for Zentalis to compete effectively. The company's long-term success depends on the successful development and commercialization of its drug candidates.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share data is approximate and may vary based on source. Investment decisions should be based on thorough research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Zentalis Pharmaceuticals Llc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2020-04-03 | CEO, President & Director Ms. Julie M. Eastland M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 166 | Website https://zentalis.com |
Full time employees 166 | Website https://zentalis.com | ||
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. The company develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. It also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.